The study, a randomized double-blind, placebo-controlled, in-patient Phase I trial conducted in up to 64 adult volunteers, will examine the safety and immunogenicity of a single dose of the Escherichia coli (ETEC)-cholera vaccine, designated Peru-15 pCTB, at up to four escalating dose levels compared against placebo.
Anthony Marucci, interim president and CEO of Avant, said: “This vaccine builds on the clinical successes to date of our single-dose, oral typhoid fever and cholera vaccines, and represents the next important milestone towards our goal of developing a safe, oral, rapid-acting ‘super enteric’ vaccine that combines protection against multiple diseases in a single product.”